PAIGE OMNISCREEN Trademark

Trademark Overview

On Thursday, August 22, 2024, a trademark application was filed for PAIGE OMNISCREEN with the United States Patent and Trademark Office. The USPTO has given the PAIGE OMNISCREEN trademark a serial number of 98712617. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Tuesday, May 27, 2025. This trademark is owned by Paige.AI, Inc.. The PAIGE OMNISCREEN trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

medical testing services using digital and diagnostic assays for detecting and predicting biomarkers based on AI algorithms applied to Hematoxylin and Eosin (HandE) digital pathology slides; medical testing services using digital and diagnostic assays for AI biomarker module for detecting and predicting genetic and phenotypic biomarkers and mutations across multiple cancer types using HandEstained pathology slides

Scientific and technological services, namely, scientific research, analysis, and testing in the fields of pathology, histology, and medical images; Providing temporary use of online non-downloadable software for digital and diagnostic assays for detecting and predicting biomarkers based on AI algorithms applied to Hematoxylin and Eosin (HandE) digital pathology slides; Providing temporary use of online non-downloadable software for digital and diagnostic assays for AI biomarker module for detecting and predicting genetic and phenotypic biomarkers and mutations across multiple cancer types using HandE-stained pathology slides
paige omniscreen

General Information

Serial Number98712617
Word MarkPAIGE OMNISCREEN
Filing DateThursday, August 22, 2024
Status653 - SUSPENSION LETTER - MAILED
Status DateTuesday, May 27, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicesmedical testing services using digital and diagnostic assays for detecting and predicting biomarkers based on AI algorithms applied to Hematoxylin and Eosin (HandE) digital pathology slides; medical testing services using digital and diagnostic assays for AI biomarker module for detecting and predicting genetic and phenotypic biomarkers and mutations across multiple cancer types using HandEstained pathology slides
Goods and ServicesScientific and technological services, namely, scientific research, analysis, and testing in the fields of pathology, histology, and medical images; Providing temporary use of online non-downloadable software for digital and diagnostic assays for detecting and predicting biomarkers based on AI algorithms applied to Hematoxylin and Eosin (HandE) digital pathology slides; Providing temporary use of online non-downloadable software for digital and diagnostic assays for AI biomarker module for detecting and predicting genetic and phenotypic biomarkers and mutations across multiple cancer types using HandE-stained pathology slides

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 22, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, May 8, 2025
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePaige.AI, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10036

Trademark Events

Event DateEvent Description
Thursday, August 22, 2024NEW APPLICATION ENTERED
Wednesday, January 22, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 6, 2025NON-FINAL ACTION WRITTEN
Thursday, March 6, 2025NON-FINAL ACTION E-MAILED
Thursday, March 6, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 8, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 27, 2025ASSIGNED TO EXAMINER
Thursday, May 8, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 8, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 27, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, May 27, 2025SUSPENSION LETTER WRITTEN
Tuesday, May 27, 2025LETTER OF SUSPENSION E-MAILED

Related Keywords

omniscreen paige digital pathology detecting biomarkers assays slides predicting diagnostic using medical